BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30947657)

  • 1. The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer.
    Qu J; Kamal MA; Yuan C
    Curr Pharm Des; 2019; 25(8):856-861. PubMed ID: 30947657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
    Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer.
    Chen Y; Bi F; An Y; Yang Q
    J Cell Biochem; 2019 Sep; 120(9):14444-14454. PubMed ID: 31034644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Long Non-Coding RNAs in Ovarian Cancer.
    Nikpayam E; Tasharrofi B; Sarrafzadeh S; Ghafouri-Fard S
    Iran Biomed J; 2017 Jan; 21(1):3-15. PubMed ID: 27664137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    Song J; Zhang W; Wang S; Liu K; Song F; Ran L
    Int J Oncol; 2018 Aug; 53(2):866-876. PubMed ID: 29749482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC).
    Malgundkar SH; Tamimi Y
    Hum Genet; 2024 Feb; 143(2):107-124. PubMed ID: 38276976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression.
    Guo Q; Cheng Y; Liang T; He Y; Ren C; Sun L; Zhang G
    Sci Rep; 2015 Dec; 5():17683. PubMed ID: 26631459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
    Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
    Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA HOTTIP is a significant indicator of ovarian cancer prognosis and enhances cell proliferation and invasion.
    Zou T; Wang PL; Gao Y; Liang WT
    Cancer Biomark; 2019; 25(2):133-139. PubMed ID: 30452402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression.
    Liu Y; Zong ZH; Guan X; Wang LL; Zhao Y
    Gene; 2017 Oct; 633():42-47. PubMed ID: 28864116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer.
    Worku T; Bhattarai D; Ayers D; Wang K; Wang C; Rehman ZU; Talpur HS; Yang L
    Cell Physiol Biochem; 2017; 44(3):948-966. PubMed ID: 29179183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNAs in ovarian cancer.
    Wang JY; Lu AQ; Chen LJ
    Clin Chim Acta; 2019 Mar; 490():17-27. PubMed ID: 30553863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients.
    Xu QF; Tang YX; Wang X
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4440-4447. PubMed ID: 30058681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer.
    Zhu FF; Zheng FY; Wang HO; Zheng JJ; Zhang Q
    Pathol Oncol Res; 2018 Apr; 24(2):419-425. PubMed ID: 28578489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.
    Panoutsopoulou K; Avgeris M; Scorilas A
    Expert Rev Mol Diagn; 2018 Nov; 18(11):963-979. PubMed ID: 30338716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.
    Tripathi MK; Doxtater K; Keramatnia F; Zacheaus C; Yallapu MM; Jaggi M; Chauhan SC
    Drug Discov Today; 2018 Sep; 23(9):1635-1643. PubMed ID: 29698834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.